Pharmaxis Grants Aptar Pharma Exclusive Option to Develop and Promote High Payload Dry Powder Inhaler

17th Aug 21

Release Date: 17/08/2021 8:30am

  • Drug delivery solutions developer Aptar Pharma acquires an exclusive 12-month option for a worldwide license to the “Orbital” technology for $US2.5m plus sales royalties
  • Pharmaxis receives a US$250k upfront fee for the option grant
  • Orbital dry powder respiratory inhaler developed by Pharmaxis delivers large payloads of drug in a convenient easy-to-use format
  • Pharmaxis retains rights to inhaled mannitol products delivered via the Orbital inhaler

Read full media release - pdf

Categories: News and Media